simple as that ...right.
Sentiment: Strong Buy
Stop losses are for the uninformed and weak of heart.
Sub $7 is buy territory whether adding or opening a position that being 20% lower than the secondary. A little insurance as is reasonably possible for a company with a dream that may come true with no sales
Regarding the appointment of Amit Sharma, M.D., the new Vice President, Medical Affairs, for Keryx, it was a major accomplishment to have Dr Sharma come on board. Strong move -
Amit Sharma, M.D., is an accomplished board certified nephrologist, internist, and hypertension specialist who has a broad-based background in chronic kidney disease and dialysis. Recently, Dr. Sharma was Medical Director, Medical Affairs, at Reata Pharmaceuticals. From 2005-2012, Dr. Sharma served as a Medical Director and Senior Advisor for Liberty Dialysis, LLC, a medium-size dialysis organization with over 300 dialysis clinics. Liberty was sold in 2011 to Fresenius Medical Care AG for $1.7 billion. From 2001 to 2005, Dr. Sharma served as the Director of the Dialysis Unit and of the Chronic Kidney Disease Clinic for the Naval Medical Center, San Diego.
Dr. Sharma received his medical degree from Louisiana State University Medical Center-New Orleans. He completed his fellowship in Nephrology and Hypertension from University of California in San Diego in 2001. Dr. Sharma also has extensive experience conducting primary research and as a principal investigator for numerous clinical trials in the field of nephrology and hypertension. He has published in many respected peer reviewed journals and he is a well known presenter for national and international meetings.
Ron Bentsur, the Company's Chief Executive Officer, commented, "We are thrilled to welcome Dr. Sharma to Keryx. Dr. Sharma has a prominent national reputation and a proven track record of success within the dialysis community. I believe that Dr. Sharma's vast knowledge and
I don't think there is any reason to set a stop loss on this stock now. With no news coming other than positive news, when the stock drops like it did today it's going to fool you and the stock will bounce back quickly and probably rise further, and your stop loss will take you out of the gain. There is nothing, fundamentally, to cause this stock to drop--so don't sweat the ups and downs because the trend for the past 3 months has been jup and that will not only continue, but accelerate as the Japanese data and approval and the FDA and Euro filing approach. BUY when it's down like this.
Sentiment: Strong Buy
if tapering talks pick up more steam it may take some news to get back over $8, buying pressure likely to be weak next couple of days, even with good market winds the stock had hard time getting over $8.20 in the last few sessions
People have been comparing ACAD and KERX for a long time, I was long KERX made money now I am going to ACAD. They won and have the potential to make more money than we can. The FDA waived their secondary P3 trial, what you think they do that all the time? Name one other company the FDA told them, don't worry about doing a second confirmatory P3 Trial and then tell me that drug did not get approved. There are hundreds of biotech stocks, is there one out there? No there isn't. So hey it happens, they're winning and I want to get in now so I am not paying $30 a share a year from now. Good Luck!
And if you noticed, in their latest article, there is no statement declaring their position on ACAD. Clearly a pump and dump in progress by these shady characters. They don't have to worry about the SEC as the SEC is up a creek anyway with their own problems. How long do we have to put up with this nonsense? It's amazing, how all this garbage came to light after the election!!!